Country: United States
Language: English
Source: NLM (National Library of Medicine)
ACYCLOVIR (UNII: X4HES1O11F) (ACYCLOVIR - UNII:X4HES1O11F)
Padagis Israel Pharmaceuticals Ltd
TOPICAL
PRESCRIPTION DRUG
Acyclovir cream is a herpes simplex virus (HSV) deoxynucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. Acyclovir cream is contraindicated in patients with known hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Risk Summary Acyclovir is minimally absorbed systemically following topical route of administration, and maternal use is not expected to result in fetal exposure to the acyclovir cream [see Clinical Pharmacology (12.3) ]. Experience with topical acyclovir use in pregnant women over several decades, based on published literature including observational studies, has not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies with systemic exposure of acyclovir have been conducted. Refer to acyclovir prescribing information for additional details. The estimated b
Acyclovir cream is a white, odorless, smooth homogeneous cream. Each gram of acyclovir cream contains 50 mg (equivalent to 5% w/w) of acyclovir in an aqueous cream base. Acyclovir cream, 5% is supplied as follows: Store at or below 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
ACYCLOVIR- ACYCLOVIR CREAM PADAGIS ISRAEL PHARMACEUTICALS LTD ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ACYCLOVIR CREAM SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ACYCLOVIR CREAM. ACYCLOVIR CREAM, FOR TOPICAL USE INITIAL U.S. APPROVAL: 2002 INDICATIONS AND USAGE Acyclovir cream is a herpes simplex virus (HSV) deoxynucleoside analogue DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years of age and older. (1) DOSAGE AND ADMINISTRATION • • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • WARNINGS AND PRECAUTIONS • • ADVERSE REACTIONS • • To report SUSPECTED ADVERSE REACTIONS, contact Padagis at 1-866-634-9120 or FDA at 1-800-FDA- 1088 or www.fda.gov/medwatch. DRUG INTERACTIONS • SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PATIENT LABELING. REVISED: 3/2022 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS Apply 5 times a day for 4 days. (2) Administer immediately following the onset of cold sore lesions. (2) Cream, 50 mg (equivalent to 5% w/w) acyclovir. (3) Acyclovir cream is contraindicated in patients with known hypersensitivity to acyclovir, valacyclovir or any component of the formulation. (4) Only for topical use of recurrent HSV lesions on the external aspect of lips and the face. Acyclovir cream should not be applied on mucous membranes including in the eye or inside the mouth or nose. (5.1) There is a potential for irritation and contact sensitization. (5.2) The most common adverse reactions reported were local skin reactions at the application site. (6.1) Angioedema, anaphylaxis, contact dermatitis and eczema have been reported. (6.2) Clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with acyclovir cream. Due to minimal systemic absorption of acy Read the complete document